Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF) has announced a national distribution agreement with Healthmark Services Ltd. to bring its InnovoTEST™ Hazardous Drug Wipe Testing Kits to hospital, community, and long-term care pharmacies across Canada. Under the exclusive three-year deal, effective immediately, Healthmark will serve as the sole Canadian distributor of the kits, which were launched in August 2026. The agreement represents a meaningful step for Innovotech in building recurring testing revenue from the pharmacy and hospital market, according to CEO Craig Milne.

Key Points

  • Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF) is a life sciences services and technology company based in Edmonton, Alberta.
  • Innovotech has signed an exclusive three-year national distribution agreement with Healthmark Services Ltd. for its InnovoTEST™ Hazardous Drug Wipe Testing Kits, effective immediately.
  • Healthmark has served the Canadian healthcare market since 1990 and distributes to pharmacies coast to coast; InnovoTEST™ kits were launched in August 2026.
  • Investors may be watching whether the agreement translates into measurable recurring revenue growth within Innovotech's pharmacy and hospital testing segment.

InnovoTEST™ Kits Target Growing Hazardous Drug Surface Monitoring Requirements

Pharmacists and pharmacy technicians who handle hazardous drugs, including many chemotherapy agents, face exposure through contaminated work surfaces that show no visible signs of contamination. Based on guidance from the National Association of Pharmacy Regulatory Authorities, routine surface monitoring is an increasingly important component of hazardous drug handling programs. Innovotech's InnovoTEST™ kits allow pharmacy teams to collect surface samples, return them for analysis at accredited Canadian facilities, and receive a written report — keeping samples entirely within Canada and aligning with Canadian regulatory requirements.

Healthmark's National Reach Accelerates InnovoTEST™ Market Access

Healthmark's established coast-to-coast distribution network spanning hospital, community, and long-term care pharmacy makes it a strategically aligned partner for Innovotech. The company's existing portfolio already covers cleanroom and compounding equipment, protective equipment, quality and contamination control, and training and certification — areas that complement InnovoTEST™ kits directly. Under the agreement, both companies will jointly support pharmacy customers in setting up and maintaining hazardous drug surface monitoring programs, including wipe sampling guidance, staff training, and interpretation of test results.

Agreement Positions Innovotech to Expand Laboratory Services with Pharmacy Compounders

Beyond kit distribution, the release states the agreement positions Innovotech to expand its sterility testing and environmental monitoring services with pharmacy compounding customers across Canada. CEO Craig Milne described the deal as a meaningful step in building a recurring testing revenue stream, while Healthmark Senior Vice-President Michael Bussieres characterised InnovoTEST™ as a natural complement to Healthmark's existing contamination control solutions. The all-Canadian supply chain — developed, distributed, and analyzed domestically — is highlighted by both parties as a key differentiator supporting regulatory alignment. The immediate share price impact was not clear from available public information.